Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70269 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Marcus Fager Ferrari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden. Hauptthemen laut MEDLINE: Hemophilia A, Immune Tolerance, Factor VIII. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Swedish state (ALF-agreeement, Skånes universitetssjukhus.
Abstract (Originalsprache)
Immune tolerance induction (ITI) to eradicate an immune response against factor VIII (FVIII) has been used in hemophilia A (HA) with various success rates, costs, and treatment burden. The present study aimed to identify markers predictive of ITI success. Data were accrued from 237 patients with severe HA (FVIII level < 1%), history of persistent FVIII inhibitors ≥ 1 BU/mL and having performed ITI. Constitutional and clinical variables associated with ITI outcome were evaluated and multivariable logistic regression models developed. The F8 variant, age at inhibitor detection, and historical peak inhibitor titer were associated with ITI outcome. HLA DRB1*1501 and DQB1*0602 were linked to each other, but not associated with ITI outcome. In a multivariable‐adjusted model, large gene deletions, peak titer ≥ 25 BU/mL, and higher age at inhibitor detection were associated with a significantly lower ITI success rate. The discriminatory power of a predictive model was 0.87 (95% confidence interval [CI], 0.85–0.93) with the historical peak titer and 0.69 (95% CI, 0.64–0.80) without. We conclude that the peak inhibitor titer is a key determinant for ITI outcome and additional constitutional markers need to be defined for useful prediction in the clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
- Department of Translational Medicine, Lund University, Malmö, Sweden.
- Center for Primary Health Care Research, Department of Clinical Sciences, Lund University, Malmö, Sweden.
ORCID-Profile: Marcus Fager Ferrari, Josefin Roslund, Erik Berntorp, Jan Astermark
Förderung
- Vetenskapsrådet
- Swedish state (ALF-agreeement
- Skånes universitetssjukhus
- Baxter BioScience
- NIH HHS
- National Institutes of Health
Zitieren
APA
Fager Ferrari, M., Roslund, J., Manderstedt, E., Berntorp, E., Astermark, J., & Malmö and Hemophilia Inhibitor Genetics Study Investigators (2026). Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A. European Journal of Haematology. https://doi.org/10.1111/ejh.70269
Vancouver
Fager Ferrari M, Roslund J, Manderstedt E, Berntorp E, Astermark J, Malmö and Hemophilia Inhibitor Genetics Study Investigators. Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A. European Journal of Haematology. 2026. doi:10.1111/ejh.70269
BibTeX
@article{FagerFerrari2026,
author = {Fager Ferrari, Marcus and Roslund, Josefin and Manderstedt, Eric and Berntorp, Erik and Astermark, Jan and Malmö and Hemophilia Inhibitor Genetics Study Investigators, Malmö and Hemophilia Inhibitor Genetics Study Investigators},
title = {Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70269}
}
EUVIMED